Faculty

Gabriela Chiorean, MD

Gabriela Chiorean, MD

Associate Professor
Department of Medicine
Division of Oncology

Mailing Address

Seattle Cancer Care Alliance
825 Eastlake Ave E, G4-833
Seattle, WA 98109-1023

Admin Contact

Kate Lynch
206.288.6770
kmlynch@seattlecca.org
Fax: 206.288.6681

Specialty / Expertise

Colorectal, pancreatic and hepatobiliary cancers, as well as phase I novel therapeutics clinical trials

Research Interests

Early stage, phase 1/2 novel therapeutics clinical trials in pancreatic and gastrointestinal cancers, as well as translational research for biomarker discovery for early cancer detection and prevention

Current Research Projects

Phase 1 and 2 clinical and translational research in pancreatic and colorectal cancer

Training

Dr. Chiorean received her medical degree from University of Medicine and Pharmacy, Cluj-Napoca, Romania. Her residency was completed at William Beaumont Hospital, Royal Oak, MI. She was a post-Doctoral fellow in Hematology-Oncology at University of Minnesota, Minneapolis, MN.

Selected Publications

Hardacre JM, Mulcahy M, Small W, Talamonti M, Obel J, Krishnamurthi S, Rocha-Lima CS, Safran H, Lenz HJ, Chiorean EG. Addition of Algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. J Gastrointestinal Surgery Nov 15 2012 online: DOI 10.1007/s11605-012-2064-6

Liu X, Song B, Liu S, Rice S, Elzey S, Konieczny SF, Ratliff T, Hazbun T, Chiorean EG. Plk1 phosphorylation of Orc2 and Hbo1 contributes to gemcitabine resistance in pancreatic cancer. Mol Cancer Ther 2012

Chiorean EG, Sanghani S, Schiel MA, Yu M, Burns M, Tong Y, Hinkle DT, Coleman N, Robb B, LeBlanc J, Clark R, Bufill J, Curie C, Loehrer PJ, Cardenes H. Phase II and gene expression analysis trial of preoperative capecitabine plus irinotecan followed by capecitabine-based radiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53. October 2011 Cancer Chemotherapy and Pharmacology 2012; 70:25-32.

Mahadevan D, Chiorean EG, Harris WB, Von Hoff DD, Stejskal-Barnett A, Qi W, Anthony SP, Younger AE, Rensvold DM,  Cordova F, Shelton CF, Becker MD, Garlich JR, Durden DL, Ramanathan RK. Phase I pharmacokinetic and pharmacodynamics study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumors and B-cell malignancies Eur J Cancer 2012 Aug 23; PMID: 22921184

Daud AI, Krishnamurthi SS, Saleh MN, Gitlitz BJ, Borad MJ, Gold PJ, Chiorean EG, Springett GM, Abbas R, Agarwal S, Bardy-Bouxin N, Hsyu PH, Leip E, Turnbull K, Zacharchuk C, Messersmith W. Phase I study of bosutinib, a Src/Abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors. Clin Cancer Res 2012 Feb 3. Epub PMID 22179664.

Chiorean EG, Ramasubbhaiah R, Yu M, Picus J, Bufill JA, Tong Y, Johnston EL, Currie C, Loehrer PJ. Multicenter phase II trial of erlotinib with docetaxel in advanced hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101. The Oncologist 2012; 17(1):13. Epub 2011 Dec 30

Abou-Alfa GK, Chan SL, Lin CC, Chiorean EG, Holcombe RF, Mulcahy MF, Carter WD, Wilson WR, Melink TR, Gutheil JC, Tsao CJ. PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2011; 68: 539-545.

Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Sharp LL, Torigian DA, O’Dwyer PJ, Vonderheide RH. CD40 activation regulates cancer inflammation and induces regression of pancreatic carcinoma in mice and humans. Science 2011; Mar 25; 331:1612-1616.

Weiss GJ, Infante JR, Chiorean EG, Borad M, Bendell J, Molina J, Tibes R, Ramanathan RK, Lewandowski K, Jones SF, Kroll S, Langmuir VK, Lee H, Burris H. Phase I study of the safety, tolerability and pharmacokinetics of TH-302, a hypoxia-activated prodrug in patients with advanced solid malignancies. Clin Cancer Res 2011; 17(9): 2997-3004.

Yang Y, Liu H, Li Z, Zhao Z, Yip-Schneider M, Fan Q, Schmidt CM, Chiorean EG, Xie J, Cheng L, Chen JH, Zhang JT. Role of fatty acid synthase in gemcitabine and radiation resistance of pancreatic cancers. Int J Biochem Mol Biol 2011; 2: 89-98.

Tolcher A, Sweeney CJ, Papadopoulos K, Patnaik A, Chiorean EG, Mita AC, Sankhala K, Furfine E, Gokemeijer J, Iacono L, Eaton C, Silver BA, Mita M. Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clin Cancer Res 2011; 17: 363-371

Cardenes H, Moore AM, Johnson CS, Yu M, Helft P, Chiorean EG, Vinson J, Howard T, Stephens AW, Tai DF, Loehrer PJ. A phase II study of Gemcitabine in combination with radiation therapy in patients with localized, unresectable pancreatic cancer: a Hoosier Oncology Group study. Am J Clin Oncol 2011; 34:460-465. 

Heath EI, Chiorean EG, Sweeney CJ, Hodge JP, Lager JJ, Forman K, Malburg L, Arumugham T, Dar MM, Suttle AB, Gainer SD, LoRusso P. A phase I study of the pharmacokinetic and safety profile of oral pazopanib dosing with a high-fat or low-fat meal in patients with advanced solid tumors. Clin Pharmacol Ther 2010; 88: 818-823.

Sweeney C, Chiorean EG, Verschraegen CF, Lee FC, Jones S, Royce M, Tye L, Liau KF, Bello A, Chao R, Burris HA. A Phase I Study of Sunitinib plus Capecitabine in patients with advanced solid tumors. J Clin Oncol 2010; 28: 4513-4520.

Akisik F, Sandrasegaran K, Bu G, Lin C, Hutchins GD, Chiorean EG. Pancreatic cancer: Utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy. Radiology 2010; 256(2): 441-449.

Chiorean EG, Malireddy S, Younger AE,  Jones DR, Waddell MJ, Margol M, Yu M, Hall SD, Schneider B, Sweeney CJ. A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2010; 66(3): 441-448.

Chiorean EG, Dragovich T, Hamm J, Barrios CH, Gorini CFN, Langmuir VK, Kroll S, Jung DT, Tidmarsh GT, Loehrer PJ. A Phase 2 Trial of Glufosfamide in combination with Gemcitabine in chemotherapy-naive pancreatic adenocarcinoma. Amer J Clin Oncol 2010; 33:111-116.

Chiorean EG, Dragovich T, Hamm J, Langmuir VK, Kroll S, Jung DT, Colowick AB, Tidmarsh GF, Loehrer PJ. A phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2007; Jul 28 PMID: 17661038; 2008:61: 1019-1026.

Chiorean EG, Porter J, Foster AE, Al Omari ASH, Yoder CA, Fife KL, Yu M, Strother RM, Murry DJ, Jones DR, Sweeney CJ. A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane naïve malignancies. Clinical Cancer Research 2008; 14: 1131-1137.

Cardenes H, Chiorean EG, DeWitt J, Schmidt M, Loehrer PJ. Locally advanced pancreatic cancer: current therapeutic approach. Oncologist 2006; 11: 612-623.

 

Last updated: Dec 2012

Top